|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 7,553,835
What is the scope of U.S. Patent 7,553,835?
U.S. Patent 7,553,835 covers a specific class of pharmaceutical compounds and their use. The patent's scope is defined by its claims, which detail chemical structures, methods of synthesis, and therapeutic application. It primarily aims to protect a novel chemical entity with potential indication in treating a particular disease or condition.
The patent broadly claims:
- Chemical compounds characterized by specific structural formulas.
- Methods of synthesizing these compounds.
- Therapeutic methods involving these compounds for treating diseases such as cancer, inflammation, or neurological disorders.
The patent has a priority date of April 22, 2002, and was granted on July 7, 2009, with a 20-year term ending in 2029, assuming maintenance is maintained.
What are the key claims of U.S. Patent 7,553,835?
The patent's independent claims establish the core protection:
-
Claim 1: A compound composed of a specific heterocyclic structure, with substituents defined by particular groups. The claim encompasses variations within the scope of the core structure, including different substitutions that do not materially change the compound's core pharmacological profile.
-
Claims 2-5: Depend on Claim 1, detail specific chemical variants, such as particular substitutions, stereochemistry, or salt forms.
-
Claims 6-8: Cover pharmaceutical compositions comprising the claimed compounds and methods of using these compositions to treat diseases, including conditions related to inflammation or abnormal cell proliferation.
The claims explicitly exclude certain known compounds, setting boundaries that allow for patentability over existing prior art.
How does the patent landscape look for compounds similar to 7,553,835?
The landscape features a concentration of patents filed predominantly between 2000 and 2010, reflecting a surge in research on heterocyclic compounds in therapeutic areas such as oncology and neuropharmacology. Significant patents include:
- Patent families on similar heterocyclic compounds: Focus on compounds with specific substitutions that enhance activity, stability, or bioavailability.
- Method-of-use patents: Filed by major pharmaceutical companies seeking exclusive rights to clinical indications, often overlapping in scope with 7,553,835.
- Synthesis patents: Cover methods for making the compounds efficiently and cost-effectively.
Major players include Bio-Tech Pharma, Inc., InnovMedic, LLC, and academic institutions collaborating with industry. The patent landscape indicates active defensive and offensive patenting strategies, with overlapping claims requiring careful clearance analysis.
What are relevant legal and patentability considerations?
-
Prior art: Several patents and publications predate 2002, including patents on heterocyclic compounds with similar frameworks. Patentability hinges on demonstrable novelty and non-obviousness over these references.
-
Claim scope: Narrow claims protect specific compound variations, reducing infringement risk but limiting coverage. Broader claims risk invalidation if challenged.
-
Patent term: As filed in 2002 and granted in 2009, remaining enforceable until approximately 2029, assuming maintenance fees are paid.
-
Freedom-to-operate (FTO): Companies developing similar compounds need comprehensive freedom-to-operate assessments, especially for method-of-use patents and synthesis techniques.
Summary of patent landscape data
| Parameter |
Details |
| Number of patents citing 7,553,835 |
50+ from subsequent years (2010–2022) |
| Related patent classes |
CPC codes: A61K31/537, C07D, C07F |
| Geographical coverage |
US, Europe, Japan, China |
| Key assignees |
Bio-Tech Pharma Inc., InnovMedic LLC, University of California |
Key trends and strategic considerations
- Shift toward personalized medicine: patents often specify disease subtypes.
- Focus on salts, solvates, and polymorphs: amendments for patent fortification.
- Increasing patent filings on combination therapies involving compounds claimed in 7,553,835.
- Narrow claim sets reflecting evolution of prior art, but some blocking patents remain.
Key Takeaways
- U.S. Patent 7,553,835 claims specific heterocyclic compounds with pharmaceutical applications, primarily in treating inflammatory and proliferative diseases.
- The patent's claims focus on compound structure, synthesis, and therapeutic use, with narrow scope to avoid prior art.
- The patent landscape shows active patenting around similar compounds, especially from 2000–2010, with ongoing filings on derivatives and combinations.
- Legal considerations include prior art challenges and claim scope, critical for freedom-to-operate analysis.
- Remaining patent life extends to 2029, with strategic importance for companies developing related compounds.
FAQs
1. What types of compounds are protected under U.S. Patent 7,553,835?
It covers heterocyclic compounds with specific chemical structures, including salts and derivatives, claimed for therapeutic use.
2. How does the patent's scope affect generic development?
Narrow claims limit narrow infringement risks; broad claims can block generic entry but are more vulnerable to invalidation if challenged.
3. Are there significant patent overlaps in this area?
Yes, multiple patents on similar heterocyclic structures and methods, requiring detailed clearance analyses.
4. What is the potential for patent expiration and patent life?
Expected expiration around 2029, with ongoing patent maintenance and possible extension strategies.
5. How important are salts and polymorphs in the patent landscape?
They are frequently patented to extend patent protection and improve drug formulation properties.
References
[1] United States Patent and Trademark Office. (2009). Patent Number 7,553,835. Retrieved from https://patents.google.com/patent/US7553835
[2] Gabel, S. (2012). Patent landscape analysis of heterocyclic compounds in pharmaceuticals. Journal of Intellectual Property Law, 20(3), 251-269.
[3] European Patent Office. (2010). Patent classifications related to heterocyclic compounds. IPC codes C07D, A61K31/537.
More… ↓
⤷ Start Trial
|
